Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

RNA molecule identified as a growth driver in various types of cancer

No. 42c | 30/06/2020 | by Koh

A special RNA molecule ensures faster growth and stops cell ageing in many types of cancer. This was discovered by scientists from the German Cancer Research Center (DKFZ) and partners in the German Consortium for Translational Cancer Research (DKTK) at the University Hospital Freiburg. If this RNA is switched off, the cell no longer has sufficient building blocks for DNA synthesis and cell division is slowed down. In future, the researchers plan to investigate whether the RNA molecule is suitable as a potential target for new cancer therapies.

Non-protein-coding RNA molecules perform a variety of functional, regulatory or structural tasks in the cell.
© Adobe Stock

Over 75 percent of the human genome is translated into RNA, but only two percent of the genome codes for proteins. The non-protein-coding RNA molecules perform a variety of functional, regulatory or structural tasks in the cell.

Non-coding RNA molecules with a length of more than 200 nucleotides are called lncRNAs (long non-coding RNAs). In recent years, more than 10,000 different molecules of this class have been discovered and their number is constantly increasing. For a long time, they were not attributed a special function. However, scientists are increasingly recognizing that they play an important role in various biological processes.

Detailed analyses have shown that lncRNAs in cancer cells are often characteristically deregulated. They can act as cancer drivers by interfering with cellular processes that promote malignancy: for example, they influence viability, the ability to divide and migrate, programmed cell death or angiogenesis.

Scientists therefore regard cancer-typically deregulated lncRNAs as promising target structures for new therapeutic approaches. Sven Diederichs from the German Cancer Research Center (DKFZ) and the German Consortium for Tranlational Cancer Research (DKTK) in Freiburg has now started a targeted search for lncRNAs that might have a role in the development of liver cancer. Liver cancer is regarded as the fourth most frequent cause of cancer-related deaths worldwide: The number of new cases is increasing in many parts of the world, but treatment options are still limited.

Diederichs and his team sceened 200 liver cell cancer patient samples for lncRNAs that were strongly overrepresented in the cancer cells. During this investigation, the researchers discovered the lncRNA "lincNMR" (long intergenic noncoding RNA nucleotide metabolism regulator). In liver cancer cell lines, but also in breast and lung cancer cell lines, switching off lincNMR sometimes drastically slowed down the cell division rate and also accelerated cell aging.

In vivo experiments confirmed the researchers that cancer cells whose lincNMR was switched off grew into smaller tumors. For these investigations, the scientists used chorioallantoic membranes in incubated chicken eggs to avoid the use of laboratory animals.

The examination of tissue samples from numerous types of cancer, including bladder and cervical tumors and various forms of lung cancer, consistently showed that lincNMR is significantly overrepresented in the tumor - compared to healthy normal tissue.

In a detailed molecular characterization, Diederichs and his team found that lincNMR plays an important role in controlling the nucleotide metabolism of the cell. If lincNMR is switched off, the cell no longer has sufficient building blocks for DNA synthesis, and cell division is slowed down.
"Overall, our results suggest that lincNMR is an RNA molecule of broad relevance to various cancers. In many cases, cancer growth seems to depend on the availability of sufficient amounts of lincNMR to the cells. Therefore, RNA might also be an attractive target structure for new therapeutic approaches. We intend to further investigate this in future investigations," summarises Sven Diederichs.

Minakshi Gandhi, Matthias Groß, Jessica M. Holler, Si'Ana A. Coggins, Nitin Patil, Joerg H. Leupold, Mathias Munschauer, Monica Schenone, Christina R. Hartigan, Heike Allgayer, Baek Kim and Sven Diederichs: The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer.
Nature Communications 2020,

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS